Pharmacological modulation of chemokine receptor function
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
G protein‐coupled chemokine receptors and their peptidergic ligands are interesting therapeutic targets due to their involvement in various immune‐related diseases, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease, HIV‐1 infection and cancer. To tackle these diseases, a lot of effort has been focused on discovery and development of small‐molecule chemokine receptor antagonists. This has been rewarded by the market approval of two novel chemokine receptor inhibitors, AMD3100 (CXCR4) and Maraviroc (CCR5) for stem cell mobilization and treatment of HIV‐1 infection respectively. The recent GPCR crystal structures together with mutagenesis and pharmacological studies have aided in understanding how small‐molecule ligands interact with chemokine receptors. Many of these ligands display behaviour deviating from simple competition and do not interact with the chemokine binding site, providing evidence for an allosteric mode of action. This review aims to give an overview of the evidence supporting modulation of this intriguing receptor family by a range of ligands, including small molecules, peptides and antibodies. Moreover, the computer‐assisted modelling of chemokine receptor–ligand interactions is discussed in view of GPCR crystal structures. Finally, the implications of concepts such as functional selectivity and chemokine receptor dimerization are considered. LINKED ARTICLES This article is part of a themed section on the Molecular Pharmacology of G Protein‐Coupled Receptors (GPCRs). To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue‐6. To view the 2010 themed section on the same topic visit http://onlinelibrary.wiley.com/doi/10.1111/bph.2010.159.issue‐5/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease
Berger, E. A., Murphy, P. M., & Farber, J. M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.657 · Cited by 2,180 · cited 1×
“Namely, CCR5 and CXCR4 facilitate HIV-1 entry to macrophages and T-cells respectively (Berger et al., 1999).”
BackgroundGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947 · cited 2×
“C, CC, CXC, CX3C) on the basis of the number and spacing of conserved cysteine residues in their N-termini (Figure 1) (Alexander et al., 2011).”
BackgroundStructure, Function, and Inhibition of Chemokines
Fernandez, E. J., & Lolis, E. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.091901.115838 · Cited by 609 · cited 2×
“The binding to CRS1 is dominated by ionic interactions between positively charged residues in the chemokine and negatively charged amino acids at the N-terminus and extracellular surface of the receptor, including sulfonated tyrosines (Fernandez and Lolis, 2002; Colvin et al., 2006; Allen et al., 2007; Veldkamp et al.…”
BackgroundTuning inflammation and immunity by chemokine sequestration: decoys and more
Mantovani, A., Bonecchi, R., & Locati, M. (2006) · Nature Reviews Immunology · doi:10.1038/nri1964 · Cited by 481 · cited 2×
“…non-G protein-signalling (so-called decoy) chemokine receptors (i.e. D6, DARC and CCX CKR) are thought to be primarily involved in scavenging a (wide) variety of inflammatory chemokines from the extracellular microenvironment, thereby limiting the recruitment of leukocytes (Mantovani et al., 2006).”
Background
Cited by
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex
Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G. W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., et al. (2013) · Science · doi:10.1126/science.1241475 · Cited by 712
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Generic GPCR residue numbers – aligning topology maps while minding the gaps
Isberg, V., de Graaf, C., Bortolato, A., Cherezov, V., Katritch, V., Marshall, F. H., Mordalski, S., Pin, J.-P., Stevens, R. C., Vriend, G., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.001 · Cited by 492
Self-citationCrystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine
Qin, L., Kufareva, I., Holden, L. G., Wang, C., Zheng, Y., Zhao, C., Fenalti, G., Wu, H., Han, G. W., Cherezov, V., et al. (2015) · Science · doi:10.1126/science.1261064 · Cited by 381
Metadata
- Authors
- Scholten, D., Canals, M., Maussang, D., Roumen, L., Smit, M., Wijtmans, M., de Graaf, C., Vischer, H., & Leurs, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-02-22
- Volume
- 165
- Issue
- 6
- Pages
- 1617-1643
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1724443945
- Cited by
- 248
- References
- 6
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.